Please note: The information displayed on this page might be outdated.
TRIGR Therapeutics: TRIGR is developing a bispecific antibody platform (BsAb) with 4 compounds in the pipeline, one clinical stage, dual angiogenesis inhibitor (TR009) and 3 immunomodulatory dual checkpoint and T cell engaging bsabs. The company has a strategic partnership with leading Korean pharma, ABL Bio (recent IPO on KOSDAQ, mkt cap $900M), whereby ABL Bio serves as TRIGR’s exclusive R&D and discovery arm for these and future bsab assets.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Oncology, Ophthalmology
Listing
Private
Website:
Address:
4790 Irvine Blvd
Suite 105-578
Irvine, CA 92620
United States

Company Participants at Boston Private Company Showcase

  • Miranda Toledano, CFO